Serodiagnosis of mycobacterium abscessus complex infection in cystic fibrosis

European Respiratory Journal

Volumn 46, Issue 3, 2015, Pages 707-716

  Qvist, Tavs ^a   Pressler, Tania ^a   Taylor Robinson, David ^b   Katzenstein, Terese L ^a   Høiby, Niels ^c  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; BLOOD ANALYSIS; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DENMARK; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM ABSCESSUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPRODUCIBILITY; RESPIRATORY TRACT INFECTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SPUTUM CULTURE; ATYPICAL MYCOBACTERIUM; CASE CONTROL STUDY; CHILD; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MICROBIOLOGY; MULTIVARIATE ANALYSIS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NEEDS ASSESSMENT; PREDICTIVE VALUE; PRESCHOOL CHILD; PREVALENCE; PROCEDURES; RISK ASSESSMENT; SEROLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DENMARK; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NEEDS ASSESSMENT; NONTUBERCULOUS MYCOBACTERIA; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK ASSESSMENT; SEROLOGIC TESTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84942793570     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00011815     Document Type: Article

References (37)

1. Leung JM, Olivier KN. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis. Curr Opin Pulm Med 2013; 19: 662-669.
2. Qvist T, Pressler T, Høiby N, et al. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res 2014; 15: 41.
3. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381: 1551-1560.
4. Esther CR Jr, Esserman DA, Gilligan P, et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-123.
5. Griffith DE. Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis 2007; 20: 198-203.
6. Martiniano SL, Sontag MK, Daley CL, et al. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014; 11: 36-44.
7. Pai M. Diagnosis of pulmonary tuberculosis: recent advances. J Indian Med Assoc 2013; 111: 332-336.
8. Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis. PLoS Med 2011; 8: e1001074.
9. Cocito CG. Properties of the mycobacterial antigen complex A60 and its applications to the diagnosis and prognosis of tuberculosis. Chest 1991; 100: 1687-1693.
10. Bukhary ZA. Evaluation of anti-A60 antigen IgG enzyme-linked immunosorbent assay for serodiagnosis of pulmonary tuberculosis. Ann Thorac Med 2007; 2: 47-51.
11. Khurshid S, Afzal M, Khalid R, et al. Improving sensitivity for serodiagnosis of tuberculosis using TB16.3-echA1 fusion protein. Tuberculosis 2014; 94: 519-524.
12. Abebe F, Holm-Hansen C, Wiker HG, et al. Progress in serodiagnosis of Mycobacterium tuberculosis infection. Scand J Immunol 2007; 66: 176-191.
13. Okuda Y, Maekura R, Hirotani A, et al. Rapid serodiagnosis of active pulmonary Mycobacterium tuberculosis by analysis of results from multiple antigen-specific tests. J Clin Microbiol 2004; 42: 1136-1141.
14. Baumann R, Kaempfer S, Chegou NN, et al. Serologic diagnosis of tuberculosis by combining Ig classes against selected mycobacterial targets. J Infect 2014; 69: 581-589.
15. Pressler T, Karpati F, Granström M, et al. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros 2009; 8: 37-42.
16. Skov M, Pandey JP, Pressler T, et al. Immunoglobulin allotypes and IgG subclass antibody response to Aspergillus fumigatus in cystic fibrosis patients. J Cyst Fibros 2004; 3: 173-178.
17. Döring G, Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun 1983; 42: 197-201.
18. Mauch RM, Levy CE. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: a systematic review. J Cyst Fibros 2014; 13: 499-507.
19. Kappler M, Nagel F, Feilcke M, et al. Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment. J Cyst Fibros 2014; 13: 534-541.
20. Daines C, VanDeVanter D, Khan U, et al. Serology as a diagnostic tool for predicting initial Pseudomonas aeruginosa acquisition in children with cystic fibrosis. J Cyst Fibros 2014; 13: 542-549.
21. Ratjen F, Walter H, Haug M, et al. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007; 42: 249-255.
22. Oliver A, Maiz L, Canton R, et al. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001; 32: 1298-1303.
23. Ferroni A, Sermet-Gaudelus I, Le Bourgeois M, et al. Measurement of immunoglobulin G against mycobacterial antigen A60 in patients with cystic fibrosis and lung infection due to Mycobacterium abscessus. Clin Infect Dis 2005; 40: 58-66.
24. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
25. Esther CR Jr, Hoberman S, Fine J, et al. Detection of rapidly growing mycobacteria in routine cultures of samples from patients with cystic fibrosis. J Clin Microbiol 2011; 49: 1421-1425.
26. Qvist T, Gilljam M, Jönsson B, et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros 2015; 14: 46-52.
27. Closs O, Harboe M, Axelsen NH, et al. The antigens of Mycobacterium bovis, strain BCG, studied by crossed immunoelectrophoresis: a reference system. Scand J Immunol 1980; 12: 249-263.
28. Pedersen SS, Espersen F, Høiby N, et al. Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis. J Clin Microbiol 1990; 28: 747-755.
29. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002; 23: 553-567.
30. Wu AH. Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy. Curr Heart Fail Rep 2013; 10: 434-440.
31. Jacobson RH. Validation of serological assays for diagnosis of infectious diseases. Rev Sci Tech 1998; 17: 469-526.
32. Menzies D. Hammering the point home: serologic testing costs more and harms more patients than other strategies for the diagnosis of active tuberculosis in India. Evid Based Med 2012; 17: 58-59.
33. Hjelt K, Højlyng N, Howitz P, et al. The role of mycobacteria other than tuberculosis (MOTT) in patients with cystic fibrosis. Scand J Infect Dis 1994; 26: 569-576.
34. Hermansen T, Lillebaek T, Hansen AB, et al. QuantiFERON-TB Gold In-Tube test performance in Denmark. Tuberculosis 2014; 94: 616-621.
35. Hermansen TS, Thomsen VØ, Lillebaek T, et al. Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. PLoS One 2014; 9: e93986.
36. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29: 1043-1051.
37. Nessar R, Cambau E, Reyrat JM, et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012; 67: 810-818.